Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation.

Miles LA, Crespi GA, Doughty L, Parker MW.

Sci Rep. 2013;3:1302. doi: 10.1038/srep01302.

2.

Structural basis of C-terminal β-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease.

La Porte SL, Bollini SS, Lanz TA, Abdiche YN, Rusnak AS, Ho WH, Kobayashi D, Harrabi O, Pappas D, Mina EW, Milici AJ, Kawabe TT, Bales K, Lin JC, Pons J.

J Mol Biol. 2012 Aug 24;421(4-5):525-36. doi: 10.1016/j.jmb.2011.11.047. Epub 2011 Dec 13.

PMID:
22197375
3.

Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient.

Roher AE, Maarouf CL, Daugs ID, Kokjohn TA, Hunter JM, Sabbagh MN, Beach TG.

J Alzheimers Dis. 2011;24(2):315-25. doi: 10.3233/JAD-2011-101809.

4.

Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N‑truncated Abeta in sporadic Alzheimer disease cases and mouse models.

Bouter Y, Lopez Noguerola JS, Tucholla P, Crespi GA, Parker MW, Wiltfang J, Miles LA, Bayer TA.

Acta Neuropathol. 2015 Nov;130(5):713-29.

PMID:
26467270
5.

His-tag binding by antibody C706 mimics β-amyloid recognition.

Teplyakov A, Obmolova G, Canziani G, Zhao Y, Gutshall L, Jung SS, Gilliland GL.

J Mol Recognit. 2011 Jul-Aug;24(4):570-5. doi: 10.1002/jmr.1069. Epub 2010 Sep 14.

PMID:
20842634
6.

Crystal structure of the amyloid-β p3 fragment provides a model for oligomer formation in Alzheimer's disease.

Streltsov VA, Varghese JN, Masters CL, Nuttall SD.

J Neurosci. 2011 Jan 26;31(4):1419-26. doi: 10.1523/JNEUROSCI.4259-10.2011.

7.

Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β.

Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, Messer J, Oroszlan K, Rauchenberger R, Richter WF, Rothe C, Urban M, Bardroff M, Winter M, Nordstedt C, Loetscher H.

J Alzheimers Dis. 2012;28(1):49-69. doi: 10.3233/JAD-2011-110977.

PMID:
21955818
8.

How cholesterol constrains glycolipid conformation for optimal recognition of Alzheimer's beta amyloid peptide (Abeta1-40).

Yahi N, Aulas A, Fantini J.

PLoS One. 2010 Feb 5;5(2):e9079. doi: 10.1371/journal.pone.0009079.

9.

Crystallization and preliminary X-ray diffraction analysis of the Fab portion of the Alzheimer's disease immunotherapy candidate bapineuzumab complexed with amyloid-β.

Crespi GA, Ascher DB, Parker MW, Miles LA.

Acta Crystallogr F Struct Biol Commun. 2014 Mar;70(Pt 3):374-7. doi: 10.1107/S2053230X14001642. Epub 2014 Feb 20.

10.

Humoral immune response to fibrillar beta-amyloid peptide.

Miller DL, Currie JR, Mehta PD, Potempska A, Hwang YW, Wegiel J.

Biochemistry. 2003 Oct 14;42(40):11682-92.

PMID:
14529278
11.

Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific.

Zago W, Buttini M, Comery TA, Nishioka C, Gardai SJ, Seubert P, Games D, Bard F, Schenk D, Kinney GG.

J Neurosci. 2012 Feb 22;32(8):2696-702. doi: 10.1523/JNEUROSCI.1676-11.2012.

12.

Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies.

Crespi GA, Hermans SJ, Parker MW, Miles LA.

Sci Rep. 2015 Apr 16;5:9649. doi: 10.1038/srep09649.

13.

Structure inducing ionic liquids-enhancement of alpha helicity in the Abeta(1-40) peptide from Alzheimer's disease.

Debeljuh N, Barrow CJ, Henderson L, Byrne N.

Chem Commun (Camb). 2011 Jun 14;47(22):6371-3. doi: 10.1039/c1cc10377f. Epub 2011 May 6.

PMID:
21547327
14.

Conformations and biological activities of amyloid beta peptide 25-35.

Millucci L, Ghezzi L, Bernardini G, Santucci A.

Curr Protein Pept Sci. 2010 Feb;11(1):54-67. Review.

PMID:
20201807
15.

The synaptic protein neuroligin-1 interacts with the amyloid β-peptide. Is there a role in Alzheimer's disease?

Dinamarca MC, Weinstein D, Monasterio O, Inestrosa NC.

Biochemistry. 2011 Sep 27;50(38):8127-37. doi: 10.1021/bi201246t. Epub 2011 Sep 1.

PMID:
21838267
16.

Structures of Abeta-related peptide--monoclonal antibody complexes.

Gardberg A, Dice L, Pridgen K, Ko J, Patterson P, Ou S, Wetzel R, Dealwis C.

Biochemistry. 2009 Jun 16;48(23):5210-7. doi: 10.1021/bi9001216.

17.

Copper abolishes the beta-sheet secondary structure of preformed amyloid fibrils of amyloid-beta(42).

House E, Mold M, Collingwood J, Baldwin A, Goodwin S, Exley C.

J Alzheimers Dis. 2009;18(4):811-7. doi: 10.3233/JAD-2009-1235.

18.

Bapineuzumab alters aβ composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy.

Roher AE, Cribbs DH, Kim RC, Maarouf CL, Whiteside CM, Kokjohn TA, Daugs ID, Head E, Liebsack C, Serrano G, Belden C, Sabbagh MN, Beach TG.

PLoS One. 2013;8(3):e59735. doi: 10.1371/journal.pone.0059735. Epub 2013 Mar 21.

19.

Low-n oligomers as therapeutic targets of Alzheimer's disease.

Ono K, Yamada M.

J Neurochem. 2011 Apr;117(1):19-28. doi: 10.1111/j.1471-4159.2011.07187.x. Epub 2011 Feb 9. Review.

20.

Spectrofluorimetric analysis of the interaction of amyloid peptides with neuronal nitric oxide synthase: implications in Alzheimer's disease.

Padayachee ER, Whiteley CG.

Biochim Biophys Acta. 2011 Dec;1810(12):1136-40. doi: 10.1016/j.bbagen.2011.09.002. Epub 2011 Sep 10.

PMID:
21930189
Items per page

Supplemental Content

Write to the Help Desk